Cargando…

Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review

PURPOSE: Whilst the treatment paradigm for colorectal cancer has evolved significantly over time, there is still a lack of reliable biomarkers of treatment response. Treatment decisions are based on high-risk features such as advanced TNM stage and histology. The role of the tumour microenvironment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mui, Milton, Clark, Molly, Vu, Tamara M. S. H., Clemons, Nicholas, Hollande, Frédéric, Roth, Sara, Ramsay, Robert, Michael, Michael, Heriot, Alexander G., Kong, Joseph C. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564805/
https://www.ncbi.nlm.nih.gov/pubmed/37816905
http://dx.doi.org/10.1007/s00423-023-03133-7
_version_ 1785118557050241024
author Mui, Milton
Clark, Molly
Vu, Tamara M. S. H.
Clemons, Nicholas
Hollande, Frédéric
Roth, Sara
Ramsay, Robert
Michael, Michael
Heriot, Alexander G.
Kong, Joseph C. H.
author_facet Mui, Milton
Clark, Molly
Vu, Tamara M. S. H.
Clemons, Nicholas
Hollande, Frédéric
Roth, Sara
Ramsay, Robert
Michael, Michael
Heriot, Alexander G.
Kong, Joseph C. H.
author_sort Mui, Milton
collection PubMed
description PURPOSE: Whilst the treatment paradigm for colorectal cancer has evolved significantly over time, there is still a lack of reliable biomarkers of treatment response. Treatment decisions are based on high-risk features such as advanced TNM stage and histology. The role of the tumour microenvironment, which can influence tumour progression and treatment response, has generated considerable interest. Patient-derived explant cultures allow preservation of native tissue architecture and tumour microenvironment. The aim of the scoping review is to evaluate the utility of patient-derived explant cultures as a preclinical model in colorectal cancer. METHODS: A search was conducted using Ovid MEDLINE, EMBASE, Web of Science, and Cochrane databases from start of database records to September 1, 2022. We included all peer-reviewed human studies in English language which used patient-derived explants as a preclinical model in primary colorectal cancer. Eligible studies were grouped into the following categories: assessing model feasibility; exploring tumour microenvironment; assessing ex vivo drug responses; discovering and validating biomarkers. RESULTS: A total of 60 studies were eligible. Fourteen studies demonstrated feasibility of using patient-derived explants as a preclinical model. Ten studies explored the tumour microenvironment. Thirty-eight studies assessed ex vivo drug responses of chemotherapy agents and targeted therapies. Twenty-four studies identified potential biomarkers of treatment response. CONCLUSIONS: Given the preservation of tumour microenvironment and tumour heterogeneity, patient-derived explants has the potential to identify reliable biomarkers, treatment resistance mechanisms, and novel therapeutic agents. Further validation studies are required to characterise, refine and standardise this preclinical model before it can become a part of precision medicine in colorectal cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-03133-7.
format Online
Article
Text
id pubmed-10564805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105648052023-10-12 Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review Mui, Milton Clark, Molly Vu, Tamara M. S. H. Clemons, Nicholas Hollande, Frédéric Roth, Sara Ramsay, Robert Michael, Michael Heriot, Alexander G. Kong, Joseph C. H. Langenbecks Arch Surg Systematic Review PURPOSE: Whilst the treatment paradigm for colorectal cancer has evolved significantly over time, there is still a lack of reliable biomarkers of treatment response. Treatment decisions are based on high-risk features such as advanced TNM stage and histology. The role of the tumour microenvironment, which can influence tumour progression and treatment response, has generated considerable interest. Patient-derived explant cultures allow preservation of native tissue architecture and tumour microenvironment. The aim of the scoping review is to evaluate the utility of patient-derived explant cultures as a preclinical model in colorectal cancer. METHODS: A search was conducted using Ovid MEDLINE, EMBASE, Web of Science, and Cochrane databases from start of database records to September 1, 2022. We included all peer-reviewed human studies in English language which used patient-derived explants as a preclinical model in primary colorectal cancer. Eligible studies were grouped into the following categories: assessing model feasibility; exploring tumour microenvironment; assessing ex vivo drug responses; discovering and validating biomarkers. RESULTS: A total of 60 studies were eligible. Fourteen studies demonstrated feasibility of using patient-derived explants as a preclinical model. Ten studies explored the tumour microenvironment. Thirty-eight studies assessed ex vivo drug responses of chemotherapy agents and targeted therapies. Twenty-four studies identified potential biomarkers of treatment response. CONCLUSIONS: Given the preservation of tumour microenvironment and tumour heterogeneity, patient-derived explants has the potential to identify reliable biomarkers, treatment resistance mechanisms, and novel therapeutic agents. Further validation studies are required to characterise, refine and standardise this preclinical model before it can become a part of precision medicine in colorectal cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-03133-7. Springer Berlin Heidelberg 2023-10-10 2023 /pmc/articles/PMC10564805/ /pubmed/37816905 http://dx.doi.org/10.1007/s00423-023-03133-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Systematic Review
Mui, Milton
Clark, Molly
Vu, Tamara M. S. H.
Clemons, Nicholas
Hollande, Frédéric
Roth, Sara
Ramsay, Robert
Michael, Michael
Heriot, Alexander G.
Kong, Joseph C. H.
Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
title Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
title_full Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
title_fullStr Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
title_full_unstemmed Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
title_short Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
title_sort use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: a scoping review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564805/
https://www.ncbi.nlm.nih.gov/pubmed/37816905
http://dx.doi.org/10.1007/s00423-023-03133-7
work_keys_str_mv AT muimilton useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT clarkmolly useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT vutamaramsh useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT clemonsnicholas useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT hollandefrederic useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT rothsara useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT ramsayrobert useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT michaelmichael useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT heriotalexanderg useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview
AT kongjosephch useofpatientderivedexplantsasapreclinicalmodelforprecisionmedicineincolorectalcancerascopingreview